• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Paynela Appoints Healthcare Technology Veteran William Febbo to Board of Directors

    7/30/25 12:00:00 PM ET
    $OPRX
    Real Estate
    Real Estate
    Get the next $OPRX alert in real time by email

    Former OptimizeRX CEO Brings Extensive Digital Health and Pharmaceutical Patient Assistance Expertise to AI-Driven Healthcare Financing Company

    Paynela, a leading healthcare financing company revolutionizing claim processing through artificial intelligence that leverages AI advancements to process thousands of medical claims in under a minute, today announced the appointment of William Febbo to its Board of Directors, effective immediately. Febbo brings over 30 years of experience in healthcare technology, digital health innovation, and pharmaceutical patient assistance programs to the rapidly growing company.

    From 2016 to 2025, Febbo served as Chief Executive Officer and Director of OptimizeRX Corporation (NASDAQ:OPRX). During his tenure, he transformed OptimizeRX from a single point-of-care product into a comprehensive omnichannel platform serving top pharmaceutical companies. Under his leadership, the company became a leading provider of digital health solutions, enhancing communication between life sciences companies, healthcare providers, and patients, specifically improving access to medications through financial assistance programs.

    "We are thrilled to welcome William to our Board of Directors," said Mary-Beth Macaluso, CEO of Paynela. "His deep expertise in pharmaceutical patient assistance programs, digital health technology, and his proven track record of scaling healthcare companies make him an invaluable addition to our team. William's experience aligns perfectly with our mission to eliminate financial barriers between patients and the medications they need."

    Febbo currently serves as Office of the Chairman at Oxbridge Health, where he continues to champion innovative healthcare solutions focused on cost transparency and predictability. He also serves on the Board of Directors at LifeMD and as Faculty/Mentor at MIT's LinQ program, supporting the next generation of healthcare entrepreneurs and scientists.

    "I'm honored to join Paynela's board at such a pivotal time. The company's mission to ensure patients receive the support they need quickly, transparently, and in full, resonates deeply with me. I've spent my career focused on solutions that attempt to declutter the patient journey, with a vision toward building systems that are both innovative and enduring for all the stakeholders. I look forward to supporting Paynela as it continues to lead with purpose, integrity, and impact."

    Mr. Febbo's appointment comes at a pivotal moment for Paynela. The company was recently recognized as a 2024 AWS Generative AI Trailblazer, highlighting its leadership in applying AI to automate and accelerate healthcare data review. Paynela's platform has delivered a 320x increase in processing speed, thanks to its use of advanced generative AI technologies.

    Mr. Febbo's appointment comes at a pivotal time for Paynela, which was recently named a 2024 AWS Generative AI Trailblazer in recognition of its automated, AI-driven solution for healthcare data review. The company's innovative platform has achieved remarkable efficiency gains, increasing processing speed by 320x through the use of generative AI technology.

    Throughout his career, Febbo has demonstrated a strong record of building and investing in disruptive healthcare technology ventures. He previously founded MedPanel, LLC, a healthcare market research firm serving top-tier corporate and financial clients in the life sciences sector, and Plexuus, LLC, which provided compliant payment solutions for medical professionals.

    Febbo earned a Bachelor of Science in International Studies and Spanish from Dickinson College and pursued further studies in Economics at Universidad de Málaga. His background includes extensive experience in fundraising, team building, product development, and strategic growth, particularly in startups, M&A, and business development.

    "William's appointment reinforces our commitment to assembling a world-class board with deep healthcare technology expertise," added Macaluso. "His insights into the pharmaceutical industry's evolving needs around patient assistance programs will be instrumental as we continue to expand our AI-driven solutions and scale our operations."

    About Paynela

    Paynela is committed to connecting patients with care by reimagining every aspect of affordable care programs. The company's mission is to leverage innovation and technology to ensure that affordable care funds intended for patients reach their destination quickly, efficiently, and in full. Paynela's core services include:

    • NelaClaim - AI-driven claims processing engine that delivers speed, accuracy, and efficiency of claims adjudication so that patients receive their funds faster
    • NelaPay - Direct-to-patient payment options that ensure patients receive all of their funds, on their terms
    • NelaView - Intuitive patient portal that empowers patients to manage and own their affordability funds directly in a simple and easy way

    Founded in 2024, Paynela has quickly established itself as a leader in healthcare financing innovation, helping pharmaceutical manufacturers streamline patient assistance programs while eliminating delays that historically impacted patient access to medications. The company was recognized as a 2024 AWS Generative AI Trailblazer for its groundbreaking automated solution that processes medical claims with unprecedented speed and accuracy.

    For more information about Paynela, visit paynela.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250730459896/en/

    Kyle Lindenboom

    [email protected]

    Get the next $OPRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPRX

    DatePrice TargetRatingAnalyst
    1/8/2025$7.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    12/20/2024$5.50Equal-Weight
    Stephens
    7/25/2024$18.50Buy
    B. Riley Securities
    4/4/2024$15.00Mkt Outperform
    JMP Securities
    1/3/2024$15.00Equal Weight
    Barclays
    2/2/2023$30.00Buy
    B. Riley Securities
    11/1/2022$19.00Buy
    Stifel
    7/15/2022$38.00Outperform
    SVB Leerink
    More analyst ratings

    $OPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    OptimizeRx downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously

    1/8/25 8:17:01 AM ET
    $OPRX
    Real Estate

    Stephens initiated coverage on OptimizeRx with a new price target

    Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50

    12/20/24 7:46:38 AM ET
    $OPRX
    Real Estate

    B. Riley Securities resumed coverage on OptimizeRx with a new price target

    B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $18.50

    7/25/24 8:24:56 AM ET
    $OPRX
    Real Estate

    $OPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth

    WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company's Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the Company's leadership bench and CEO Steve Silvestro's commitment to aligning talent and structure with OptimizeRx's long-term strategic objectives under his management. "Over the past six months, I have had the opportunity to ev

    8/19/25 7:30:00 AM ET
    $OPRX
    Real Estate

    OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

    Q2 revenue of $29.2 million, increased 55% year-over-yearQ2 gross profit increased 59% year-over-year to $18.6 millionPaid down $4.5 million of principal on outstanding term loan during Q2Increased full year 2025 guidance to a revenue range between $104 million and $108 million and adjusted EBITDA range between $14.5 million and $17.5 million WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended June 30, 2025. Quarterly comparisons are

    8/7/25 4:01:00 PM ET
    $OPRX
    Real Estate

    Paynela Appoints Healthcare Technology Veteran William Febbo to Board of Directors

    Former OptimizeRX CEO Brings Extensive Digital Health and Pharmaceutical Patient Assistance Expertise to AI-Driven Healthcare Financing Company Paynela, a leading healthcare financing company revolutionizing claim processing through artificial intelligence that leverages AI advancements to process thousands of medical claims in under a minute, today announced the appointment of William Febbo to its Board of Directors, effective immediately. Febbo brings over 30 years of experience in healthcare technology, digital health innovation, and pharmaceutical patient assistance programs to the rapidly growing company. From 2016 to 2025, Febbo served as Chief Executive Officer and Director of Op

    7/30/25 12:00:00 PM ET
    $OPRX
    Real Estate

    $OPRX
    SEC Filings

    View All

    OptimizeRx Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - OptimizeRx Corp (0001448431) (Filer)

    8/19/25 7:44:18 AM ET
    $OPRX
    Real Estate

    SEC Form 10-Q filed by OptimizeRx Corporation

    10-Q - OptimizeRx Corp (0001448431) (Filer)

    8/8/25 4:02:36 PM ET
    $OPRX
    Real Estate

    OptimizeRx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OptimizeRx Corp (0001448431) (Filer)

    8/7/25 4:13:02 PM ET
    $OPRX
    Real Estate

    $OPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $OPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lang James Paul bought $2,443,761 worth of shares (321,408 units at $7.60), increasing direct ownership by 472% to 389,452 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    3/19/25 7:40:24 PM ET
    $OPRX
    Real Estate

    CEO Febbo William J bought $100,220 worth of shares (20,000 units at $5.01), increasing direct ownership by 3% to 601,253 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    12/16/24 2:28:39 PM ET
    $OPRX
    Real Estate

    Director Klema Cathy was granted 9,868 shares, increasing direct ownership by 84% to 21,620 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    6/12/25 4:36:16 PM ET
    $OPRX
    Real Estate

    Director Lang James Paul was granted 9,868 shares, increasing direct ownership by 3% to 399,320 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    6/12/25 4:35:31 PM ET
    $OPRX
    Real Estate

    Director Spangler Patrick D was granted 9,868 shares, increasing direct ownership by 22% to 55,335 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    6/12/25 4:34:57 PM ET
    $OPRX
    Real Estate

    $OPRX
    Financials

    Live finance-specific insights

    View All

    OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

    Q2 revenue of $29.2 million, increased 55% year-over-yearQ2 gross profit increased 59% year-over-year to $18.6 millionPaid down $4.5 million of principal on outstanding term loan during Q2Increased full year 2025 guidance to a revenue range between $104 million and $108 million and adjusted EBITDA range between $14.5 million and $17.5 million WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended June 30, 2025. Quarterly comparisons are

    8/7/25 4:01:00 PM ET
    $OPRX
    Real Estate

    OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET

    WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, August 7, 2025, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Thursday, August 7, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)T

    7/17/25 7:30:00 AM ET
    $OPRX
    Real Estate

    OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

    Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended March 31, 2025. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the first quarter of 2025

    5/12/25 4:05:00 PM ET
    $OPRX
    Real Estate

    $OPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    12/6/24 4:26:03 PM ET
    $OPRX
    Real Estate

    SEC Form SC 13G filed by OptimizeRx Corporation

    SC 13G - OptimizeRx Corp (0001448431) (Subject)

    11/14/24 3:18:35 PM ET
    $OPRX
    Real Estate

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    11/14/24 11:25:34 AM ET
    $OPRX
    Real Estate

    $OPRX
    Leadership Updates

    Live Leadership Updates

    View All

    OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth

    WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company's Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the Company's leadership bench and CEO Steve Silvestro's commitment to aligning talent and structure with OptimizeRx's long-term strategic objectives under his management. "Over the past six months, I have had the opportunity to ev

    8/19/25 7:30:00 AM ET
    $OPRX
    Real Estate

    Paynela Appoints Healthcare Technology Veteran William Febbo to Board of Directors

    Former OptimizeRX CEO Brings Extensive Digital Health and Pharmaceutical Patient Assistance Expertise to AI-Driven Healthcare Financing Company Paynela, a leading healthcare financing company revolutionizing claim processing through artificial intelligence that leverages AI advancements to process thousands of medical claims in under a minute, today announced the appointment of William Febbo to its Board of Directors, effective immediately. Febbo brings over 30 years of experience in healthcare technology, digital health innovation, and pharmaceutical patient assistance programs to the rapidly growing company. From 2016 to 2025, Febbo served as Chief Executive Officer and Director of Op

    7/30/25 12:00:00 PM ET
    $OPRX
    Real Estate

    OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors

    WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company's Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025. Mr. Silvestro joined the Company in 2019 and has been the Company's CEO since March 2025, after serving as the interim CEO from January 2025. The appointment of Mr. Silvestro, with his knowledge of the Company and expertise in the industry, will enhance overall leadership and gre

    6/24/25 7:30:00 AM ET
    $OPRX
    Real Estate